Turn recording back on
Role of RANKL inhibition in osteoporosis.
McClung M.
Arthritis Res Ther. 2007;9 Suppl 1:S3. Review.
PMID: 17634142 [PubMed - indexed for MEDLINE]
Related Articles Free article in PMC
RANK ligand inhibition with denosumab for the management of osteoporosis.
Lewiecki EM.
Expert Opin Biol Ther. 2006 Oct;6(10):1041-50. Review.
PMID: 16989586 [PubMed - indexed for MEDLINE]
Related Articles
Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
Bai YD, Yang FS, Xuan K, Bai YX, Wu BL.
Med Hypotheses. 2008 Aug;71(2):256-8. Epub 2008 Apr 28.
PMID: 18445511 [PubMed - indexed for MEDLINE]
Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies.
McClung MR.
Curr Osteoporos Rep. 2006 Mar;4(1):28-33. Review.
PMID: 16527005 [PubMed - indexed for MEDLINE]
Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases.
Delmas PD.
J Clin Densitom. 2008 Apr-Jun;11(2):325-38. Epub 2008 Apr 2. Review.
PMID: 18375161 [PubMed - indexed for MEDLINE]
[OPG/RANKL: role and therapeutic target in osteoporosis]
Marie P, Halbout P.
Med Sci (Paris). 2008 Jan;24(1):105-10. French.
PMID: 18198124 [PubMed - indexed for MEDLINE]
Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA.
Drugs Today (Barc). 2008 Jan;44(1):7-21. Review.
PMID: 18301800 [PubMed - indexed for MEDLINE]
RANKL inhibition in the treatment of bone metastases.
Lipton A, Jun S.
Curr Opin Support Palliat Care. 2008 Sep;2(3):197-203. Review.
PMID: 18685421 [PubMed - indexed for MEDLINE]
Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis.
Curr Opin Investig Drugs. 2007 Apr;8(4):299-303. Review.
PMID: 17458179 [PubMed - indexed for MEDLINE]
Clinical development of anti-RANKL therapy.
Schwarz EM, Ritchlin CT.
Arthritis Res Ther. 2007;9 Suppl 1:S7. Review.
PMID: 17634146 [PubMed - indexed for MEDLINE]
[New pathophysological relevant metabolic pathways in osteoporosis. Future innovative therapies?]
Neumann E.
Z Rheumatol. 2006 Sep;65(5):400, 402-6. German.
PMID: 16924451 [PubMed - indexed for MEDLINE]
[Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases]
Mera K, Ito K.
Clin Calcium. 2007 Jan;17(1):37-46. Review. Japanese.
PMID: 17211092 [PubMed - indexed for MEDLINE]
[RANKL inhibition as therapy for joint damage]
Akama H.
Nihon Rinsho Meneki Gakkai Kaishi. 2007 Oct;30(5):404-7. Review. Japanese.
PMID: 17984581 [PubMed - indexed for MEDLINE]
The RANKL/RANK/OPG pathway.
Boyce BF, Xing L.
Curr Osteoporos Rep. 2007 Sep;5(3):98-104.
PMID: 17925190 [PubMed - indexed for MEDLINE]
Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
Tankó LB.
Curr Opin Investig Drugs. 2007 Oct;8(10):830-5. Review.
PMID: 17907059 [PubMed - indexed for MEDLINE]
Osteoprotegerin as a potential therapy for osteoporosis.
Curr Osteoporos Rep. 2005 Dec;3(4):121-5. Review.
PMID: 16303111 [PubMed - indexed for MEDLINE]
Is cortical bone hip? What determines cortical bone properties?
Epstein S.
Bone. 2007 Jul;41(1 Suppl 1):S3-8. Epub 2007 Mar 19. Review.
PMID: 17466615 [PubMed - indexed for MEDLINE]
Biology of RANK, RANKL, and osteoprotegerin.
Arthritis Res Ther. 2007;9 Suppl 1:S1. Review.
PMID: 17634140 [PubMed - indexed for MEDLINE]
Osteoporosis: integrating biomarkers and other diagnostic correlates into the management of bone fragility.
McCormick RK.
Altern Med Rev. 2007 Jun;12(2):113-45. Review.
PMID: 17604458 [PubMed - indexed for MEDLINE]
RANKL inhibition: from mice to men (and women).
Stolina M, Kostenuik PJ, Dougall WC, Fitzpatrick LA, Zack DJ.
Adv Exp Med Biol. 2007;602:143-50. Review.
PMID: 17966399 [PubMed - indexed for MEDLINE]